Selective Dose Escalation for Esophageal Cancer

Status unconfirmed · Phase 2

Conditions studied: Esophageal Cancer

In brief

This prospective study was designed to assess the outcomes (survival and failure patterns) of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy) with concurrent continuous infusion 5-fluorouracil (5-FU) and weekly carboplatin/paclitaxel. Patients with less than complete response (CR) or partial response (PR) received dose escalation of radiation to 59.4 Gy with the same chemotherapy.

Key facts

Study ID

NCT00139633

Run by

The Oregon Clinic

People needed

25

Starts

2000-07-01

Expected to finish

2005-06-01

Last updated by the study team

2005-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• T1-4, N0-1, M0-1a esophageal carcinoma

You may not qualify if…

• distant metastases

Where it is running

• The Oregon Clinic — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.